

Anthony Joshua

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/76307/publications.pdf>

Version: 2024-02-01

123
papers

16,027
citations

81889

39
h-index

20955

115
g-index

125
all docs

125
docs citations

125
times ranked

20270
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144.	27.0	3,128
2	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. <i>New England Journal of Medicine</i> , 2014, 371, 424-433.	27.0	2,456
3	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet, The</i> , 2014, 384, 1109-1117.	13.7	1,588
4	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	27.0	982
5	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	7.4	857
6	Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. <i>Annals of Oncology</i> , 2019, 30, 582-588.	1.2	641
7	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	1.6	627
8	[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2021, 397, 797-804.	13.7	552
9	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021, 385, 1196-1206.	27.0	376
10	Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2397.	7.4	359
11	Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. <i>Modern Pathology</i> , 2008, 21, 1451-1460.	5.5	254
12	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	7.0	222
13	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109.	8.2	211
14	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). <i>Journal of Clinical Oncology</i> , 2018, 36, 1232-1239.	1.6	207
15	Pembrolizumab. , 2015, 3, 36.		171
16	Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. <i>Annals of Oncology</i> , 2019, 30, 1370-1380.	1.2	171
17	Three-Color FISH Analysis of TMPRSS2/ERG Fusions in Prostate Cancer Indicates That Genomic Microdeletion of Chromosome 21 Is Associated with Rearrangement. <i>Neoplasia</i> , 2006, 8, 465-469.	5.3	165
18	Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. <i>Cancer Genetics and Cytogenetics</i> , 2006, 169, 128-137.	1.0	151

#	ARTICLE	IF	CITATIONS
19	Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 5-9.	3.6	150
20	A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. <i>Annals of Oncology</i> , 2016, 27, 454-460.	1.2	142
21	Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 15-22.	1.9	131
22	AR Signaling and the PI3K Pathway in Prostate Cancer. <i>Cancers</i> , 2017, 9, 34.	3.7	118
23	Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. <i>Annals of Oncology</i> , 2013, 24, 2972-2977.	1.2	117
24	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019, 125, 1341-1349.	4.1	115
25	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	2.8	97
26	Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 773-785.	4.2	94
27	Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. <i>Annals of Oncology</i> , 2015, 26, 2044-2056.	1.2	89
28	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. <i>British Journal of Cancer</i> , 2019, 120, 1113-1119.	6.4	83
29	Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. , 2014, 2, 41.		80
30	A phase 2 study of tremelimumab in patients with advanced uveal melanoma. <i>Melanoma Research</i> , 2015, 25, 342-347.	1.2	79
31	PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. <i>Modern Pathology</i> , 2013, 26, 435-447.	5.5	73
32	Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3005-3005.	1.6	58
33	TheraP: A randomised phase II trial of ¹⁷⁷ Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5500-5500.	1.6	58
34	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	2.8	57
35	Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. <i>Clinical Cancer Research</i> , 2015, 21, 1621-1627.	7.0	51
36	Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. <i>British Journal of Cancer</i> , 2016, 115, 1186-1192.	6.4	50

#	ARTICLE	IF	CITATIONS
37	Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. <i>European Journal of Cancer</i> , 2019, 107, 1-7.	2.8	48
38	A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2014, 74, 1544-1550.	2.3	45
39	Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 959-969.	2.3	43
40	Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e229-e233.	1.9	42
41	Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. <i>European Urology</i> , 2015, 67, 441-447.	1.9	40
42	Therapeutic implications of germline genetic findings in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 386-396.	27.6	39
43	Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. <i>Anti-Cancer Drugs</i> , 2010, 21, 206-209.	1.4	36
44	Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. <i>Oncology Letters</i> , 2016, 11, 1581-1585.	1.8	34
45	UpFrontPSMA: a randomized phase 2 study of sequential ¹⁷⁷ Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). <i>BJU International</i> , 2021, 128, 331-342.	2.5	33
46	A randomized phase II trial of geriatric assessment and management for older cancer patients. <i>Supportive Care in Cancer</i> , 2018, 26, 109-117.	2.2	32
47	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Oncologist</i> , 2019, 24, 1188-1194.	3.7	32
48	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 837-846.	1.6	29
49	Prostate Cancer as a Model System for Genetic Diversity in Tumors. <i>Advances in Cancer Research</i> , 2011, 112, 183-216.	5.0	28
50	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 80, 275-279.	1.9	28
51	Phase I/II Trial of the Combination of ¹⁷⁷ Lutetium Prostate specific Membrane Antigen 617 and Idronecil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN). <i>European Urology Oncology</i> , 2021, 4, 963-970.	5.4	27
52	Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. <i>Genome Medicine</i> , 2021, 13, 81.	8.2	25
53	Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. <i>Journal of Geriatric Oncology</i> , 2015, 6, 23-28.	1.0	24
54	A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone. <i>Journal of Geriatric Oncology</i> , 2016, 7, 81-89.	1.0	24

#	ARTICLE	IF	CITATIONS
55	Prostatic preneoplasia and beyond. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2008, 1785, 156-181.	7.4	23
56	Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome. <i>Cancer Research</i> , 2014, 74, CT104-CT104.	0.9	23
57	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. <i>EBioMedicine</i> , 2021, 72, 103625.	6.1	23
58	¹⁷⁷ Lu-PSMA-617 and Idroneoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 560-566.	5.0	22
59	Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3015-3015.	1.6	22
60	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA9000-LBA9000.	1.6	22
61	Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies. <i>Prostate</i> , 2011, 71, 778-790.	2.3	21
62	ENZAâ€” trial protocol: a randomized phase II trial using prostateâ€”specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castrationâ€”resistant prostate cancer treated with enzalutamide (ANZUP 1901). <i>BJU International</i> , 2021, 128, 642-651.	2.5	18
63	Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial. <i>Journal of Translational Medicine</i> , 2016, 14, 12.	4.4	17
64	Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies. <i>Hormones and Cancer</i> , 2020, 11, 155-169.	4.9	17
65	Barriers and facilitators related to undertaking physical activities among men with prostate cancer: a scoping review. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1007-1027.	3.9	17
66	Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgenâ€”receptorâ€”targeted therapy for metastatic castrationâ€”resistant prostate cancer. <i>Cancer</i> , 2021, 127, 2587-2594.	4.1	16
67	Malignant Pheochromocytoma Secreting Vasoactive Intestinal Peptide and Response to Sunitinib: A Case Report and Literature Review. <i>Endocrine Practice</i> , 2014, 20, e145-e150.	2.1	15
68	Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment. <i>Epigenomics</i> , 2020, 12, 1317-1332.	2.1	15
69	Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. <i>European Journal of Cancer</i> , 2014, 50, 2399-2407.	2.8	14
70	A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 124-129.	1.9	14
71	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. <i>European Journal of Cancer</i> , 2022, 170, 296-304.	2.8	14
72	Small Blue Cell Tumors of the Rectum. <i>Journal of Clinical Oncology</i> , 2005, 23, 912-913.	1.6	13

#	ARTICLE	IF	CITATIONS
73	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021, 157, 391-402.	2.8	13
74	Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 4964.	3.7	13
75	Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk,) <i>Tj ETQq1 1 0.784314 rgBI2/Overl</i>		
76	Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. <i>Internal Medicine Journal</i> , 2005, 35, 468-472.	0.8	11
77	Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC). , 2014, 2, .		11
78	Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS). <i>PLoS ONE</i> , 2017, 12, e0170544.	2.5	11
79	Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naïve (IPI-N) melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3000-3000.	1.6	11
80	The use of taxanes in choriocarcinoma; a case report and review of the literature. <i>Gynecologic Oncology</i> , 2004, 94, 581-583.	1.4	10
81	Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 439-445.	2.5	10
82	Health status, emergency department visits, and oncologists' feedback: An analysis of secondary endpoints from a randomized phase II geriatric assessment trial. <i>Journal of Geriatric Oncology</i> , 2019, 10, 169-174.	1.0	10
83	Developing a pan-cancer research autopsy programme. <i>Journal of Clinical Pathology</i> , 2019, 72, 689-695.	2.0	10
84	Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. <i>Clinical Cancer Research</i> , 2021, 27, 2340-2351.	7.0	10
85	The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. <i>Cancers</i> , 2020, 12, 1178.	3.7	10
86	New treatments for metastatic melanoma. <i>Cmaj</i> , 2014, 186, 754-760.	2.0	9
87	Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. <i>European Journal of Cancer</i> , 2022, 170, 285-295.	2.8	9
88	Smoking reduction does work: Resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years. <i>Respirology</i> , 2005, 10, 233-238.	2.3	8
89	Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9527-9527.	1.6	8
90	PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?. <i>Cancers</i> , 2021, 13, 4520.	3.7	8

#	ARTICLE	IF	CITATIONS
91	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e13-240.e20.	1.6	7
92	Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer. <i>Future Science OA</i> , 2018, 4, FSO253.	1.9	7
93	Fats and Mets, KRAS-Driven Lipid Dysregulation Affects Metastatic Potential in Pancreatic Cancer. <i>Cancer Research</i> , 2020, 80, 4886-4887.	0.9	7
94	Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report. <i>Annals of Oncology</i> , 2021, 32, 280-282.	1.2	7
95	Increased Treatment-Related Toxicity Subsequent to an Anti-PD-1 Agent. <i>Current Oncology</i> , 2015, 22, 320-322.	2.2	6
96	Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. <i>BMC Medicine</i> , 2022, 20, 112.	5.5	6
97	Reliable Method of Isolating Transfected Clones from the LNCaP Human Prostatic Cell Line. <i>BioTechniques</i> , 1997, 23, 66-70.	1.8	5
98	BRAF inhibition and the spectrum of granulomatous reactions. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	5
99	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz071.	2.9	4
100	To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma. <i>Cancer</i> , 2021, 127, 2333-2341.	4.1	4
101	Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5007-5007.	1.6	4
102	Effect of concomitant medication use on outcomes of treatment and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e16045-e16045.	1.6	4
103	Clinical trials for metastatic castrate-resistant prostate cancer—“who is looking after the control patients? Questions for the future. <i>Annals of Oncology</i> , 2022, 33, 574-577.	1.2	4
104	Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer. <i>Cancer Research Communications</i> , 2022, 2, 293-306.	1.7	4
105	Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 3-10.	1.1	3
106	Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5078-5078.	1.6	3
107	IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.. <i>Journal of Clinical Oncology</i> , 2015, 33, 279-279.	1.6	3
108	Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2021, 79, 177-179.	1.9	2

#	ARTICLE	IF	CITATIONS
109	Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. Journal of Clinical Oncology, 2014, 32, 5051-5051.	1.6	2
110	Cutaneous sarcoidosis due to immune-checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor. Skin Health and Disease, 0, , e71.	1.5	2
111	A review of the cutaneous toxicities of tebentafusp"Featuring two cases involving superficial bullous reactions. Australasian Journal of Dermatology, 2022, 63, .	0.7	2
112	Use of a Clinical Assistant to Screen Patients With Genitourinary Cancer to Encourage Entry into Clinical Trials and Use of Supportive Medication: A Pilot Project at a Canadian Cancer Center. Clinical Genitourinary Cancer, 2013, 11, 342-345.e1.	1.9	1
113	Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer. European Urology, 2018, 73, 736-737.	1.9	1
114	Oncology in 2050 " A Retrospective?. Oncologist, 2020, 25, e1127-e1130.	3.7	1
115	An Australian experience of pemetrexed in malignant mesothelioma (MM). Journal of Clinical Oncology, 2004, 22, 7285-7285.	1.6	1
116	Low-dose abiraterone (abi) with food in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre experience.. Journal of Clinical Oncology, 2014, 32, 5077-5077.	1.6	1
117	Do special access programs facilitate off-label prescribing? The experience of enzalutamide in prostate cancer.. Journal of Clinical Oncology, 2014, 32, 6550-6550.	1.6	1
118	Abstract 732: Using functional and chemical genomics to identify mechanisms of Enzalutamide resistance in prostate cancer. , 2015, , .		1
119	Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue. Prostate Cancer, 2022, 2022, 1-8.	0.6	1
120	Non-melanoma Skin Cancer. , 2016, , 225-232.		0
121	An Australian experience of pemetrexed in malignant mesothelioma (MM). Journal of Clinical Oncology, 2004, 22, 7285-7285.	1.6	0
122	A single-arm, phase II, multicenter trial of sunitinib (SU) in locally advanced or metastatic pheochromocytoma/paraganglioma (PC/PG): Updated interim results.. Journal of Clinical Oncology, 2014, 32, e15621-e15621.	1.6	0
123	Patient Preference or Indifference: Learning from the CABADOC Study. European Urology, 2022, 81, 241-242.	1.9	0